All News Roche Holding AG

Equities

ROG

CH0012032048

Market Closed - Swiss Exchange Other stock markets 11:31:28 2024-05-28 am EDT			5-day change	1st Jan Change
228.8 ^CHF	-0.48%		-2.39%	-6.42%

May. 27	Roche renews diagnostic partnership with Hitachi	CF
May. 27	Roche appoints Director of Corporate Business Development	CF

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Roche and Hitachi High-Tech extend their long-standing partnership	01:04am	AQ
Roche renews diagnostic partnership with Hitachi	May. 27	CF
Roche appoints Director of Corporate Business Development	May. 27	CF
Roche and Hitachi High-Tech Extend Their 46-Year Partnership, Paving the Way for Further Breakthroughs in Diagnostic Testing	May. 27	CI
Roche Announces Management and Board Committee Changes	May. 27	CI
Swiss Market Index Slumps as Economic Data Triggers Rate Jitters Anew	May. 24	MT
ROCHE HOLDINGS AG : Gets a Neutral rating from Deutsche Bank	May. 24	ZD
UK Watchdog Launches Probe into Roche's LumiraDx Purchase	May. 24	MT
Roche, LumiraDx Deal Probed by U.K. Competition Watchdog	May. 24	DJ
Roche: FDA designation for blood test	May. 22	CF
Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test	May. 22	MT
Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)	May. 22	CI
Europe stock pickers go old-school to ride the next wave in AI	May. 22	RE
Global markets live: Microsoft, Roche, BMW, Nintendo, Nordson...	May. 21
Roche: Breakthrough designation for inavolisib in breast cancer	May. 21	CF
Roche's Inavolisib Breast Cancer Treatment Gets FDA Breakthrough Therapy Designation	May. 21	DJ
Roche's Investigational Breast Cancer Treatment Granted Breakthrough Designation by US FDA	May. 21	MT
FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation	May. 21	BU
FDA Grants Breakthrough Therapy Designation to Roche's Inavolisib for Advanced Hormone Receptor-Positive, Hormone-Positive, Hormon Receptor 2-Negative Breast Cancer with A PIK3CA Mutation	May. 21	CI
UK Competition Watchdog Considers Probe into Roche's Purchase of LumiraDx Business	May. 20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ROCHE HOLDING : In line quarterly results won’t cut it for Roche

April 24, 2024 at 11:50 am EDT

Obesity: Roche joins the battle

December 04, 2023 at 10:48 am EST